Marker Therapeutics (MRKR) investor relations material

Executive summary

• Clinical-stage immuno-oncology company focused on T cell-based therapies for hematological malignancies and solid tumors, advancing MAR-T cell technology for broad-spectrum anti-tumor activity.

• Pipeline includes MT-601 for lymphoma and pancreatic cancer, and MT-401-OTS for AML, with ongoing Phase 1 APOLLO study showing objective responses and favorable safety profile.

• Manufacturing partnerships with Baylor College of Medicine and Cellipont Bioservices to support clinical and future commercial production.

Financial highlights

• Net loss for Q1 2026 was $3.2 million, a 28% improvement from $4.4 million in Q1 2025, driven by lower R&D and G&A expenses and higher grant income.

• Operating expenses decreased 18% year-over-year to $4.1 million, with R&D down 9% and G&A down 10%.

• Grant income more than doubled to $0.75 million from $0.35 million year-over-year.

• Cash, cash equivalents, and restricted cash totaled $15.6 million as of March 31, 2026.

• Working capital was $13.8 million at quarter-end, down from $16.8 million at year-end 2025.

Outlook and guidance

• Anticipates continued net losses as investment in R&D and clinical development persists.

• Current cash position expected to fund operations into Q1 2027, assuming no additional grant funding.

• Plans to seek additional capital through equity issuance and further grant applications.